NeuroSense Therapeutics (NRSN)

• Market cap: $22.1M
• 1 day: -5.93%
• 5 days: -17.78%
• 1 month: 0.91%
• 3 months: 44.91%
• 6 months: -11.90%
• Year to date: 38.75%
• 1 year: 116.00%
• 5 years: -72.52%
• 10 years: -72.52%

About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Employees: 16

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 7 [Q2] → 7 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

8.11% less ownership

Funds ownership: 9.27% [Q2] → 1.16% (-8.11%) [Q3]

85% less capital invested

Capital invested by funds: $1.87M [Q2] → $286K (-$1.59M) [Q3]